Tempus Forms Multi-omics Collaboration With Actuate Therapeutics
What You Should Know:– Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others…
Continue Reading
